Ketamine and Propofol NeuroImaging
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Propofol, Ketamine, Peripheral Nerve Stimulation.
- Who it may be relevant to
- Registry conditions: Anesthesia, Pain. Basic parameters: 18 years — 59 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This is a multi-visit which will collect MRI (pictures of the brain) and EEG (brain waves) data to determine changes in brain connectivity and brain activity for memory formation and pain perception while receiving the commonly-used anesthetic agents ketamine and propofol, both alone and in combination.
Detailed description
There are four independent drug-administration sessions, visits 1, 3, 5, and 7. In all four of these sessions, both drugs are received, but in two different sequences. Two of these are EEG sessions and two are MRI sessions. Both EEG and MRI will have the same two drug orderings:
* Propofol alone, followed by ketamine and propofol together * Ketamine alone, followed by propofol and ketamine together Assignment to propofol alone first, versus ketamine alone first will be randomized. But, all subjects will be assigned to receive both drug orderings under both EEG monitoring and MRI acquisition.
A follow-up memory testing visit will occur the day after each MRI/EEG session, on visits 2, 4, 6, and 8. No drugs are given during the next-day testing sessions.
Interventions
- Drug Propofol
Subjects will receive an intravenous infusion of this drug, during portions of the study. - Drug Ketamine
Subjects will receive an intravenous infusion of this drug, during portions of the study. - Device Peripheral Nerve Stimulation
Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with specific experimental events.
Primary outcome measures
- Explicit Memory Performance, comparing single-drug to drug-combination condition [Time frame: Visits 2, 4, 6, and 8. Visits spaced at least 1 week apart, are 1 hour in length, and are 12-36 hours after the preceding visit (1, 3, 5, and 7).]
- Pain intensity and unpleasantness ratings, comparing single-drug to drug-combination condition [Time frame: Visits 1, 3, 5, and 7: immediately following each experimental condition. These visits are 3 hours in length and spaced at least 1 week apart.]
Secondary outcome measures (4)
- MRI-based activation during memory formation, comparing the single-drug condition to the combination-drug condition [Time frame: MRI visits (1 and 3, or 5 and 7), which are are 3 hours in length and spaced at least 1 week apart. Data collected at 3 timepoints in 8-minute MRI scans: at baseline, under one drug, and under both drugs.]
- MRI-based activation during painful stimulation, comparing the single-drug condition to the combination-drug condition [Time frame: MRI visits (1 and 3, or 5 and 7), which are are 3 hours in length and spaced at least 1 week apart. Data collected at 3 timepoints in 8-minute MRI scans: at baseline, under one drug, and under both drugs.]
- MRI-based changes in functional connectivity, comparing the single-drug condition to the combination-drug condition [Time frame: MRI visits (1 and 3, or 5 and 7), which are are 3 hours in length and spaced at least 1 week apart. Data collected at 3 timepoints in 8-minute MRI scans: at baseline, under one drug, and under both drugs.]
- EEG-based changes in functional connectivity, comparing single-drug to combination-drug condition. [Time frame: EEG visits (1 and 3, or 5 and 7), which are are 3 hours in length and spaced at least 1 week apart. Data collected at 3 timepoints in 8-minute EEG scans: at baseline, under one drug, and under both drugs.]
Eligibility criteria
Inclusion criteria
- Adults 18-59 years of age, who:
- have none of the specific exclusion criteria
- have a valid email address and valid phone number throughout the study
- free from any non-MRI compatible implants
Exclusion criteria
- are pregnant or attempting to conceive
- body mass index (BMI) > 35
- significant memory impairment or hearing loss
- sleep apnea
- chronic pain or frequently taking pain medication
- chronic medical conditions requiring treatment (hypertension, diabetes, high cholesterol)
- neurologic disease, including seizures and tremor
- psychiatric diagnoses, including anxiety, depression, panic, or PTSD
- a history of any of these medical conditions: abnormal heartbeats (cardiac conduction abnormality or arrhythmia), liver or kidney disease, or significant lung disease
- severe claustrophobia or intolerance of an MRI
- have metal implants or non-removable metal piercings
- having a history of adverse reaction to ketamine or propofol
- daily alcohol or heavy alcohol use; history of alcohol abuse
- current daily smoker
- regular or recent marijuana use (including prescribed/medical marijuana)
- illicit drug use, i.e., street drugs
- regularly taking: antiepileptics, antidepressants, anti-psychotics, antihistamines, anti-anxiety medication, stimulants, or sleep-aids
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single blind
- Primary purpose
- Basic science
Study locations
United States · 1 center
- University of Pittsburgh — Pittsburgh
Identifiers
NCT: NCT07294092 · STUDY25110029 · R35GM146822